Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ARDS |
---|---|---|
09:32 ET | 1675 | 0.0715 |
10:01 ET | 15000 | 0.07345 |
11:08 ET | 400 | 0.074 |
01:44 ET | 158 | 0.076 |
02:09 ET | 300 | 0.076 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aridis Pharmaceuticals Inc | 3.3M | -0.4x | --- |
Antigenics Inc | 2.4K | 0.0x | --- |
AquaBounty Technologies Inc | 7.7M | -0.3x | --- |
Rayont Inc | 50.0 | 0.0x | --- |
Histogen Inc | 1.7M | -0.1x | --- |
Ensysce Biosciences Inc | 2.5M | -0.2x | --- |
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
---|---|
Revenue (TTM) | $22.4M |
Shares Outstanding | 44.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.18 |
Book Value | $-0.90 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.